Thoratec Corporation (NASDAQ: THOR) announced today that it has begun to enroll patients in the HeartMate III™ U.S. clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE